Drug Trial Radar · NCT04542499
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
507
Actual
Start
Sep 23, 2020
Primary completion
Jan 29, 2024
Study completion Feb 15, 2024
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are experiencing motor fluctuations.
Conditions
- Parkinson Disease
Interventions
TavapadonDrug
Participants will be randomized to receive tavapadon 5 to 15 mg tablet QD orally for 27 weeks.
PlaceboDrug
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary)Time frame: Week 26
Locations
146 sites in 14 countries. Site status is shown where the registry gives one.
Pheonix, Arizona
Phoenix, Arizona
Little Rock, Arkansas
Little Rock, Arkansas
Fountain Valley, California
Fountain Valley, California
Fresno, California
Fresno, California
Long beach, California
Long Beach, California
Los Angeles, California
Los Angeles, California
Pasadena, California
Pasadena, California
Reseda, California
Reseda, California
Denver, Colorado
Denver, Colorado
Englewood, Colorado
Englewood, Colorado
Adventura, Florida
Adventura, Florida
Atlantis, Florida
Atlantis, Florida
Boca Raton, Florida
Boca Raton, Florida
Boca Raton, Florida
Boca Raton, Florida
Coral Springs, Florida
Coral Springs, Florida
Hallandale Beach, Florida
Hallandale, Florida
Maitland, Florida
Maitland, Florida
Ocala, Florida
Ocala, Florida
Port Charlotte, Florida
Port Charlotte, Florida
Port Orange, Florida
Port Orange, Florida
Tampa, Florida
Tampa, Florida
Winter Park, Florida
Winter Park, Florida
Augusta, Georgia
Augusta, Georgia
Chicago, Illinois
Chicago, Illinois
Elk Grove Village, Illinois
Elk Grove Village, Illinois
Kansas City, Kansas
Kansas City, Kansas
Lexington, Kentucky
Lexington, Kentucky
Scarborough, Maine
Scarborough, Maine
Boston, Massachusettes
Boston, Massachusetts
Boston Neuro Research Center
North Dartmouth, Massachusetts
Farmington Hills, Michigan
Farmington Hills, Michigan
West Bloomfield, Michigan
West Bloomfield, Michigan
Saint Louis, Missouri
St Louis, Missouri
Las Vegas, Nevada
Las Vegas, Nevada
Las Vegas, Nevada
Las Vegas, Nevada
Syracuse, New York
Syracuse, New York
Asheville, North Carolina
Asheville, North Carolina
Cincinnati, Ohio
Cincinnati, Ohio
Cleveland, Ohio
Cleveland, Ohio
Columbus, Ohio
Columbus, Ohio
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.